Jasper Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
JSPR$16.37-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $71,637 | $86,887 |
| Prepaid expenses and other current assets | 4,174 | 2,051 |
| Total current assets | 75,811 | 88,938 |
| Property and equipment, net | 1,875 | 2,727 |
| Operating lease right-of-use assets | 976 | 1,467 |
| Restricted cash | 417 | 417 |
| Other non-current assets | 820 | 1,343 |
| Total assets | $79,899 | $94,892 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,027 | $4,149 |
| Current portion of operating lease liabilities | 1,089 | 972 |
| Accrued expenses and other current liabilities | 10,121 | 7,253 |
| Total current liabilities | 15,237 | 12,374 |
| Non-current portion of operating lease liabilities | 724 | 1,814 |
| Other non-current liabilities | 2,264 | 2,264 |
| Total liabilities | 18,225 | 16,452 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock: $0.0001 par value — 10,000,000 shares authorized at December 31, 2024 and 2023; none issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock: $0.0001 par value — 492,000,000 shares authorized at December 31, 2024 and 2023; 15,022,122 and 11,163,896 shares issued and outstanding at December 31, 2024 and 2023, respectively | 2 | 1 |
| Additional paid-in capital | 302,541 | 248,039 |
| Accumulated deficit | (240,869) | (169,600) |
| Total stockholders’ equity | 61,674 | 78,440 |
| Total liabilities and stockholders’ equity | $79,899 | $94,892 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.